David Siegel

Chief, Myeloma Division

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Siegel is the Chief of the Myeloma Division at the John Theurer Cancer Center in the United States. His research primarily focuses on multiple myeloma, encompassing areas such as molecular profiling, T-cell therapies, and novel treatment strategies. Recent publications highlight his work on antigen-specific T cells, liquid biopsy methods, and the efficacy of combination therapies in treating relapsed multiple myeloma.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (5)

James Kochenderfer

UNITED STATES

View details

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES

View details

Hang Quach

University of Melbourne

AUSTRALIA

View details

Christopher Seet

Assistant Professor

David Geffen School of Medicine at UCLA

UNITED STATES

View details

Albert Oriol

Institut Català d'Oncologia

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Siegel

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Combining antigen-specific T cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.

Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

Collaborators (5)

James Kochenderfer

Ola Landgren

Hang Quach

Christopher Seet

Albert Oriol

Make your next move.